Sriram Ryali

Track

Insider profile

Currently holds a position at Eiger BioPharmaceuticals Inc

Performance

Overall performance
2.7
Performance over holding periods
2.7
30 days 90 days 120 days
Average return 0% 8.2% 15.1%
Success rate 58% 68% 82%
Transactions
3 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer Eiger BioPharmaceuticals Inc Dec. 3, 2018 -
Sriram Ryali's trades of Caribou Biosciences Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
89.50
Quantity 63,427 +2.8%
Value US$1,373,163
US Codexis Inc (CDXS)
Transaction date
Purchase
Price
174.78
Quantity 35,620 -39.7%
Value US$3,599,843
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-30 2025-01-29
B Purchase
63,427 +2.8%
89.50
US$1,373,163 		63,427 +2.8% 89.50 US$1,373,163
2023-09-12 2023-09-08
US Codexis Inc (CDXS)
B Purchase
35,620 -39.7%
174.78
US$3,599,843 		35,620 -39.7% 174.78 US$3,599,843
2022-03-14 2022-03-14
S Sale
30,441 +1.1%
174.99
US$1,706,616 		30,441 +1.1% 174.99 US$1,706,616
2019-04-22 2019-04-22
B Purchase
1,250 +inf%
11.08
US$13,853 		1,250 +inf% 11.08 US$13,853